NCT05144386 - Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

November 14, 2024

Study Completion Date

November 14, 2024

Conditions

HIV-1-infection

Interventions

BIOLOGICAL

EBT-101

EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration

Trial Locations (3)

63110

Washington University, St Louis

94115

Quest Clinical Research, San Francisco

08103

Cooper Health, Camden